VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (6224)	1/5/1999 11:11:00 AM
From: Vector1	Read Replies (1) of 9719

<< I don't think 5-FU is even approved for pancreatic cancer, so it's hard for the FDA to require a comparison. >> From the SUPG Web site. <<SuperGen is conducting randomized clinical trials for patients with advanced pancreatic cancer. Patients that have had no previous chemotherapy will be randomized (have a 50:50 chance) to receive either gemcitabine (GemzarÒ) or RFS 2000. Patients who have received gemcitabine as their only prior chemotherapy, and have progressive disease will be randomized to either 5-fluorouracil (5-FU) or RFS 2000.>> 5 FU in combination with other chemo agents is the preferred protocol. Gemzar is a joke. Any reliance soley on a Gemzar comparison is risky. Yes the bar should be low but we are talking about the FDA. The bar on ALS should be low as well. The Stehlin Clinic in Houston is quite controversial. I will leave it at that. Not sure on the Extra stuff. V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next